Active Recombinant Mouse Map2k1, GST-tagged

• Cat.No.: Map2k1-666M
• Product Overview: Recombinant full-length mouse MEK1 (S218E, S222E) was expressed in E. coli cells using a N-terminal GST tag.

Specification

• Description: MEK1 (EE) is a member of the dual specificity protein kinase family that acts as a mitogen-activated protein kinase (MAPK) kinase. MEK1 lies upstream of MAPK/ERK and stimulates the enzymatic activity of MAPK/ERK upon a wide variety of extra- and intracellular signals. As an essential component of MAPK/ERK signal transduction pathway, MEK1 is involved in many cellular processes such as proliferation, differentiation, transcription regulation and development. Constitutive activation of MEK1 results in cellular transformation. Thus, MEK1 represents a likely target for pharmacologic intervention in proliferative disease such as cancer.
• Source: E.coli
• Species: Mouse
• Tag: GST
• Form: Recombinant protein stored in 50mM Tris-HCl, pH 7.5, 150mM NaCl, 0.25mM DTT, 0.1mM EGTA, 0.1mM EDTA, 0.1mM PMSF, 25% glycerol.
• Bio-activity: 326 nmol/min/mg
• Molecular Mass: ~69 kDa
• Protein length: Full Length
• Purity: >70%
• Applications: Kinase Assay, Western Blot
• Stability: 1 yr at -70°C from date of shipment.
• Storage: Store product at –70°C. For optimal storage, aliquot target into smaller quantities after centrifugation and store at recommended temperature. For most favorable performance, avoid repeated handling and multiple freeze/thaw cycles.
• Concentration: 0.1 ug/ul

Gene Information

• Gene Name: Map2k1 mitogen-activated protein kinase kinase 1 [ Mus musculus (house mouse) ]
• Official Symbol: Map2k1
• Synonyms: Map2k1; mitogen-activated protein kinase kinase 1; Mek1; MEKK1; MAPKK1; Prkmk1; dual specificity mitogen-activated protein kinase kinase 1; MEK 1; MAPKK 1; MAPK/ERK kinase 1; MAP kinase kinase 1; ERK activator kinase 1; mitogen activated protein kinase kinase 1; protein kinase, mitogen activated, kinase 1, p45; NP_032953.1; EC 2.7.12.2
• Gene ID: 26395
• mRNA Refseq: NM_008927
• Protein Refseq: NP_032953
• UniProt ID: P31938
• Chromosome Location: 9 C; 9 34.55 cM
• Pathway: ARMS-mediated activation; Activated TLR4 signalling; Acute myeloid leukemia; Androgen Receptor Signaling Pathway
• Function: ATP binding; MAP kinase kinase activity; mitogen-activated protein kinase kinase kinase binding

Reviews

08/01/2020

The unmatched performance of the MAP2K1 protein in both ELISA assays and protein electron microscopy structure analysis showcases its versatility and reliability in various experimental settings.

05/18/2016

The MAP2K1 protein finds extensive utility in protein electron microscopy structure analysis.

04/11/2016

With its exceptional specificity and sensitivity, it enables precise and reliable detection of target molecules, making it a valuable tool in the field of diagnostic and research applications.

Q&As

Are there ongoing clinical trials targeting MAP2K1?

Yes, there are clinical trials exploring the efficacy and safety of MAP2K1 inhibitors in various cancers and other diseases.

Are there diagnostic tests specifically targeting MAP2K1 in clinical practice?

Some diagnostic tests may analyze MAP2K1 mutations, especially in the context of cancer, to inform treatment decisions.

What diagnostic applications does MAP2K1 have in cancer detection?

MAP2K1 mutations can serve as biomarkers in cancer diagnostics, aiding in the identification and classification of tumors.

How does MAP2K1 contribute to drug resistance in cancer treatment?

MAP2K1 mutations can be associated with resistance to certain cancer therapies, making it important to understand its role in treatment response.

Are there targeted therapies based on MAP2K1 in cancer treatment?

Yes, MAP2K1 inhibitors are being explored as targeted therapies in cancer treatment, aiming to block the abnormal signaling associated with MAP2K1 mutations.